COST-UTILITY OF NIVOLUMAB VERSUS OBSERVATION FOR THE ADJUVANT TREATMENT OF UROTHELIAL CARCINOMA (UC) FOR PATIENTS WHO ARE AT HIGH-RISK OF RECURRENCE: A UNITED STATES (US) PAYER PERSPECTIVE
VALUE IN HEALTH（2022）
关键词
urothelial carcinoma,nivolumab versus observation,adjuvant treatment,cost-utility,high-risk
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要